sellWeak cluster of 210b5-1 plan
CHESS ROBERT sold $170k of TWST
director at Twist Bioscience Corp. 3,600 shares at an average of $47.26, traded Nov 11, 2024, filed Nov 13, 2024.
Warning score
4Value
$170k
3,600 shares
Holdings after
21,641
-14% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-126641, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +3,600 | $8.82 | $32k | 25,241 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -2,324 | $46.99 | $109k | 22,917 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -1,276 | $47.76 | $61k | 21,641 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -3,600 | $0.00 | $0 | 3,504 | Nov 13, 2024 |
Related signals
Other insiders at Twist Bioscience Corp and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 5Weak | sell 210b5-1 | TWST Twist Bioscience Corp | CHESS ROBERT director | $182k | 3,504 | |
| 15Weak | sell | TWST Twist Bioscience Corp | Cho Dennis See Remarks | $14k | 316 | |
| 23Weak | sell 2 | TWST Twist Bioscience Corp | Cho Dennis See Remarks | $6,225 | 133 | |
| 23Weak | sell 2 | TWST Twist Bioscience Corp | Cho Dennis See Remarks | $19k | 367 | |
| 31Weak | sell 2 | TWST Twist Bioscience Corp | Cho Dennis See Remarks | $72k | 1,507 | |
| 32Weak | sell 2 | TWST Twist Bioscience Corp | Cho Dennis See Remarks | $81k | 1,811 | |
| 28Weak | sell 2 | TWST Twist Bioscience Corp | Cho Dennis See Remarks | $27k | 659 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.